降低血友病患者动脉粥样硬化性心血管疾病风险:一级预防的重要性
血友病治疗进步使预期寿命显著改善,年龄相关疾病尤其是动脉粥样硬化性心血管疾病(CVD)增多。血友病患者动脉粥样硬化发生率与一般人群相似,但低凝状态使动脉血栓形成和CVD相关死亡率较低。改善止血接近正常水平的治疗范式可能使这种保护消失,而CVD危险因素在血友病患者中同样常见却似乎治疗不足,一级预防至关重要。
要点
- 血友病患者动脉粥样硬化发生率与一般人群相似,但动脉血栓形成和CVD相关死亡率较低。
- 改善止血接近正常水平的治疗范式可能使血友病患者原有的CVD保护作用消失。
- 血友病患者CVD危险因素同样常见但似乎治疗不足,需积极识别和管理肥胖、缺乏运动、高血压和高胆固醇血症。
核心结论
- 血友病患者CVD危险因素同样常见但似乎治疗不足,一级预防至关重要,因为已确诊CVD的治疗可能困难。
- 他汀类药物在一般人群已显示显著降低心血管和全因死亡率,不良事件少且不增加出血风险,其在血友病患者中的使用需要紧急评估。
- 需要进一步纵向研究来预防血友病患者CVD,包括准确的CVD风险评估,以优化预防和管理。
研究设计与样本
- 原文未报告研究设计。
主要发现
- 血友病患者动脉粥样硬化发生率与一般人群相似,但动脉血栓形成和CVD相关死亡率低得多,归因于其低凝状态。
- 改善止血接近正常水平的治疗范式可能使血友病患者被认为具有的保护作用消失。
- CVD危险因素在血友病患者中与一般人群同样常见,但似乎治疗不足。
- 他汀类药物在一般人群已显示显著降低心血管和全因死亡率,不良事件少且不增加出血风险。
关键数值与推荐
- 原文未报告具体数值或推荐等级。
临床怎么用
- 需要积极识别和管理CVD危险因素,如肥胖、缺乏运动、高血压和高胆固醇血症。
- 他汀类药物在血友病患者中的使用需要紧急评估。
- 需要进一步纵向研究来预防血友病患者CVD,包括准确的CVD风险评估。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Revolutionary advances in the treatment of hemophilia has led to a significant improvement in life expectancy. Associated with this has been an increase in age-related diseases especially atherosclerotic cardiovascular disease (CVD). While people with hemophilia (PWH) develop atherosclerosis at rates similar to those of the general population, rates of atherothrombosis and mortality related to CVD have been much lower, due to their hypocoagulable state. Changing treatment paradigms, aimed at reducing the risk of bleeding by improving hemostasis to levels approaching normality, has meant that the protection they are thought to have had may be lost. CVD risk factors are just as common in PWH as in the general population, but appear to be undertreated. In particular, primary prevention of CVD is vital in all individuals, but particularly in PWH as treatment of established CVD can be difficult. Active identification and management of CVD risk factors, such as obesity, physical inactivity, hypertension, and hypercholesterolemia, is required. In particular, statins have been shown to significantly reduce cardiovascular and all-cause mortality with few adverse events and no increased risk of bleeding in the general population, and their use needs urgent assessment in PWH. Further longitudinal research into preventing CVD in PWH, including accurate CVD risk assessment, is required to optimize prevention and management.
引用
- Dix C, Dolan G, Hunt BJ, et al. Reducing the risk of atherosclerotic cardiovascular disease in people with hemophilia: the importance of primary prevention. J Thromb Haemost. 2024. PMID: 38309435. doi:10.1016/j.jtha.2024.01.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。